Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
Ardelyx Director William C. Bertrand Jr. reported multiple equity transactions on June 18, 2025, significantly increasing his beneficial ownership position:
- Acquired 19,390 shares of common stock at $0 through the Non-Employee Director Compensation Program, choosing stock instead of cash compensation
- Received 41,551 Restricted Stock Units (RSUs) under the same program, convertible 1:1 into common shares upon vesting
- Granted stock options to purchase 54,059 shares at $3.61 per share, expiring June 18, 2035. Options vest monthly at 1/12th rate with potential acceleration at next annual stockholder meeting
Following these transactions, Bertrand directly owns 290,707 shares of common stock and 54,059 stock options. These grants reflect standard non-employee director compensation rather than open market transactions.
Ardelyx Director David M. Mott has increased his position in the company through a significant stock purchase on June 16, 2025. Mott acquired 200,000 shares of common stock at a weighted average price of $3.6294 per share, with individual trade prices ranging from $3.57 to $3.70.
Following this transaction, Mott's total beneficial ownership stands at 2,896,871 shares held directly. Of this total, 87,566 shares are held for the benefit of entities associated with New Enterprise Associates, for which Mott disclaims beneficial ownership except for his pecuniary interest.
This insider purchase by a director signals potential confidence in the company's prospects. The transaction was reported via Form 4 filing, executed through multiple trades, and was filed within the required reporting period. The filing was completed through an attorney-in-fact on June 19, 2025.
Ardelyx held its 2025 Annual Meeting of Stockholders on June 18, 2025, where shareholders voted on four key proposals. 187,162,927 shares out of 239,255,212 outstanding shares were represented at the meeting.
Key outcomes include:
- Board Elections: Class II directors David Mott and Michael Raab were elected to serve until 2028, with Raab receiving stronger shareholder support (101.2M vs 93M votes)
- Say-on-Pay: Approved with strong support (131.3M votes in favor)
- Auditor Ratification: Ernst & Young LLP confirmed as independent auditor with overwhelming approval (182.5M votes in favor)
- Equity Plan Amendment: The amendment to the Amended and Restated 2014 Equity Incentive Award Plan passed with moderate support (85M votes for vs 57.4M against)
The meeting demonstrated generally positive shareholder sentiment, though the Equity Plan Amendment faced notable opposition with approximately 40% of voting shares against the proposal.